We previously reported on infrared coagulator ablation of anal high-grade intraepithelial squamous lesions in HIV-positive and HIV-negative men who have sex with men (MSM) with a median follow-up of 1.5 years.
A lthough anal squamous-cell carcinoma (SCC) is a relatively rare cancer, its incidence, particularly in men who have sex with men (MSM), has continued to rise. 1 One recent series reported anal cancer rates of 69 and 14 per 100,000 for HIV-positive and HIV-negative MSM in a multicenter AIDS cohort study, and highly active antiretroviral therapy did not decrease the risk. 2 The paradigm for developing anal SCC mimics that of cervical cancer. Both carcinomas are believed to develop secondary to infection with oncogenic human papillomavirus (HPV), most commonly HPV 16 and 18. 3 The integration of the viral genome into epithelial cell DNA promotes malignant transformation, with progression from normal epithelium, to dysplasia, to invasive carcinoma. 4 Dysplasia may be detected in both the cervix and anus through cytologic examination of epithelial cells obtained via cervical or anal Papanicolaou smear. 5 In fact, anal cytology and high-resolution anoscopy (HRA) have detected high-grade squamous intraepithelial lesions (HSILs) in up to 52% of HIV-positive MSM. 6 Intraepithelial neoplasia, in particular, HSIL, is believed to be the precursor for both cervical and anal SCC. 7 Removal or eradication of HSIL reduces the incidence of invasive cervical cancer and may reduce the incidence of invasive anal cancer. 8 -11 Cervical HSIL is treated through partial or complete excision of the squamocolumnar transition zone by a variety of procedures, including loop electrosurgical excision, cone biopsy, or surgical excision. 12 Although the anal squamocolumnar transition zone histopathologically resembles that of the cervix, 13 it is not amenable to complete excision secondary to high risk of anal stenosis, abscess formation, anal spasm, and dyschezia. 14, 15 Instead, early management of anal HSIL has largely centered around local ablation of individual lesions with a laser, cryotherapy, or electrocautery. [15] [16] [17] [18] [19] Before 2005, only one study had evaluated the efficacy of surgical ablation of HSIL with electrocautery in 37 patients. 20 Reported recurrence rates in HIV-positive and HIV-negative subjects were 79% and 0%, although follow-up time was short and patients did not undergo reoperation. While surgical ablation was well-tolerated, in general, approximately half of the subjects experienced significant postoperative pain for a mean duration of 2.9 weeks. In an effort to more effectively treat HSIL, we developed a technique of in-office ablation with the infrared coagulator (IRC) (Redfield IRC 2100; Redfield Corporation, Rochelle Park, NJ) after administration of local anesthesia. 11 We have previously reported the short-term efficacy of this procedure in both HIV-positive and HIVnegative patients who were followed up for a median of 18 months and 19 months after their first IRC ablation, where we achieved a per-individual lesion ablation success rate of 72% in HIV-positive and 81% in HIV-negative MSM. 11, 21 Metachronous lesions (lesions at a location other than the prior treatment site) were a major cause for recurrence. After a first and second IRC ablation of HSIL, 59% and 45% of HIV-positive MSM and 45% and 22% or HIVnegative MSM developed a metachronous lesion. Median time to any recurrence in HIV-positive and HIV-negative MSM after a first IRC was 7 and 11 months. No subjects progressed to SCC.
Pineda et al 10 published results of their 10 years of experience treating HSIL in 246 patients in the operating room with standard surgery combined with in-office IRC ablation. They reported a 57% recurrence rate at a mean of 19 months (similar for both HIV-positive and HIV-negative subjects) and 1.2% progressed to SCC. At last followup, 78% were HSIL free. Here, we report a long-term follow-up of our original cohort with repeat in-office IRC ablation of biopsy-proven HSIL. It was our goal to determine whether recurrence rates, including both metachronous and persistent lesions, decreased with time. We also wanted to see whether treatment results differed between HIV-positive and HIV-negative patients and if patients progressed to invasive anal cancer.
MATERIALS AND METHODS

Identification of Subjects
With institutional review board approval from Essex Investigational Review Board and in accordance with Health Insurance Portability and Accountability Act regulations, we performed a retrospective chart review of all MSM patients who were included in the original study cohorts and underwent at least one IRC ablation of biopsy-proven intra-anal HSIL between 1999 and 2005. 11, 21 In the original study, subjects were included who had at least 6 months follow-up and were excluded if they were treated with an experimental therapeutic HPV vaccine, had extensive disease not amenable to local ablation, or demonstrated lack of follow-up. In this study, all subjects from the original cohorts were included as long as they had Ն1 year of additional follow-up. Data abstracted from patient charts included patient demographics, HIV status, dates and location of HSIL, and dates of IRC.
Identification and Management of HSIL
The standard procedure for detection and management of HSIL is similar to that reported in our previous studies. 11, 21 In brief, all subjects had a specimen for liquidbased anal cytology obtained with a wetted Dacron swab in DISEASES OF THE COLON & RECTUM VOLUME 54: 10 (2011) accordance with standard technique. 22 Following anal cytology sampling, a digital rectal examination and standard anoscopy were performed. HRA, as described by Jay et al, 23 was completed for all MSM with abnormal anal cytology reported as atypical squamous cells of undetermined significance, atypical squamous cells-cannot exclude HSIL, low-grade squamous intraepithelial neoplasia, or HSIL, or those in whom a lesion was visualized with standard anoscopy. Lesions suspicious for HSIL were photographed, biopsied, and immediately fixed in 10% formalin solution. All cytology and pathology specimens were sent to Enzo Clinical Laboratories (Farmingdale, NY) or Quest Diagnostics (Teterboro, NJ), and the results were reported in accordance with the Bethesda system. 24 MSM with localized, intra-anal, biopsy-proven HSIL were treated with inoffice IRC ablation after infiltration of local anesthetic by the technique previously reported. 11 Each lesion was identified, infiltrated with local anesthesia, and repeatedly coagulated with the IRC in 1.5-second pulses. The eschar was removed, and the process was repeated until the submucosal vessels were coagulated. All high-grade lesions present were treated at the time of ablation. All procedures were performed by a surgeon (S.G.) or a nurse practitioner experienced in HRA and IRC ablation.
Patients received routine evaluations with digital rectal examination and standard anoscopy at 3-to 6-month intervals after IRC. At 6-month intervals, we obtained anal cytology, and those with abnormalities on cytology or standard anoscopy had HRA. Patients with biopsy-proven HSIL were offered repeat IRC ablation. All patients with benign cytology or no evidence of HSIL on HRA continued follow-up.
Study Definitions
Treatment success was defined as a patient with benign cytology or no evidence of HSIL on HRA after ablation. Recurrence was classified as a patient who had cytologic or biopsy-proven HSIL. Recurrence at anytime in the same location as the previous HSIL was considered a persistent lesion, whereas recurrence in a new location was considered a metachronous lesion. Time to recurrence was the time elapsed from IRC ablation to the date of HSIL diagnosis.
Statistical Analysis
Statistical analyses were performed with SAS Version 9.2 (SAS Institute Inc., Cary, NC).
2 tests were used to compare proportions, and Student t tests were used to compare means. Probabilities of recurrence were estimated using the Kaplan-Meier product limit method with comparison between groups evaluated by the log-rank statistic. The Cox proportional hazards model was used to estimate hazard ratios (equivalent of relative risks adjusted for follow-up time) and 95% confidence intervals. In addition, general estimating equations were used to determine whether recurrence and persistence rates diminished over time following continued IRC treatment. In these general estimating equation models a Poisson distribution was assumed with a compound symmetric covariance structure where the dependent variable was the number of recurrent HSIL lesions (or the number of persistent HSIL lesions), and the offset was the natural log of the total patient days followed after each IRC treatment (or the natural log of the total lesion days followed).
RESULTS
From the original cohort of 68 HIV-positive and 75 HIVnegative MSM, 44 (65%) HIV-positive and 52 (69%) HIVnegative MSM had at least one additional year of follow-up and were included in this analysis. Thirty-five percent of HIV-positive and 31% of HIV-negative subjects from the original cohort were unavailable for analysis because they were lost to follow-up. The clinical characteristics and details of follow-up are listed in Table 1 . For the HIV-positive cohort, the median age at study inclusion was 41.5 years, with a median follow-up from first IRC ablation of 69 months, and 75% had Ͼ3 years of follow-up, and 57% had Ն5 years of follow-up. For the HIV-negative cohort, the median age at study inclusion was 35.9 years, with a median follow-up from first IRC ablation of 48 months, and 52% had Ͼ3 years of follow-up, and 27% had Ն5 years of follow-up. Ninety percent of HIV-positive MSM received their first IRC within 55 days of HSIL diagnosis, and 90% of HIV-negative MSM received their first IRC within 64 days of HSIL diagnosis. Table 2 describes HSIL recurrence rates for both HIV-positive and HIV-negative MSM. After the first IRC ablation, a greater number of both HIV-positive and HIV-negative The mean number of recurrent lesions for both HIV-positive and HIV-negative MSM was never greater than 2. HSIL recurrence rates significantly decreased with continued IRC ablation for HIV-positive MSM (P ϭ .009), but not for HIV-negative subjects (P ϭ .52). It is interesting that the number of HSIL lesions treated was not found to significantly affect recurrence by proportional hazards analysis (P Ͼ .05; data not shown). Table 3 lists the incidence of metachronous lesions following each individual IRC ablation in both HIV-positive and HIV-negative MSM. Of the 44 initially treated HIV-positive subjects, 36 (82%) developed metachronous HSILs over a mean of 17 (range, 4 -99) months after ablation. After the second and third IRC treatments, 16 (46%) and 15 (75%) patients developed metachronous lesions over a mean of 9 (range, 2-31) months and 18 (range 2-81) months. For HIV-negative MSM, 27 (52%) subjects developed metachronous lesions over a mean of 13 (range, 2-46) months. After the second and third IRC treatments, 12 (48%) and 3 (43%) subjects developed metachronous lesions over a mean of 14 (range, 5-47) months and 10 (range, 4 -17) months.
HSIL Recurrence After IRC
HSIL persistence after treatment in HIV-positive and HIV-negative MSM is shown in Table 4 . Following treatment, persistent HSILs were identified in 27 (61%) HIVpositive MSM. Of a total of 147 HSIL lesions initially treated, only 48 persisted, with a probability that a single lesion was successfully ablated of 67%. The probability that a lesion was successfully ablated increased to 77% after the second ablation. Similarly, for the HIV-negative cohort, 18 (35%) MSM developed persistent HSILs. Of 112 HSILs treated, 22 persisted, with a probability of ablating a single lesion of 80%. The probability of ablating an individual lesion increased to 82% after the second ablation.
No patients developed serious adverse events following IRC ablation, including no anal stricture formation, persistent bleeding, significant postoperative hemorrhage, failure to heal, or infection requiring antibiotic therapy. Pain was the most common postprocedure concern, and was adequately controlled by, at most, mild narcotic analgesia. Importantly, no patient developed anal SCC during the study period.
Comparison of HSIL Recurrence Between HIV-Positive and HIV-Negative MSM HSIL recurrence was significantly greater among HIVpositive than HIV-negative patients only after the first IRC ablation ( Fig. 1 , P ϭ .008). In fact, the median time to recurrence after the first IRC treatment for HIV-positive MSM (12 Ϯ 1 month) was half the median time to recurrence for HIV-negative MSM (24 Ϯ 6 months). On proportional hazards analysis, positive HIV status was found to be a significant predictor of recurrence after the first IRC ablation with a hazard ratio of 1.9 (95% CI: 1.2-3.0). Kaplan-Meier and proportional hazards analyses did not demonstrate significant differences in HSIL recurrence between HIV-positive and HIV-negative MSM after the second and third IRC treatments (Figs. 2 and 3) . However, 1 year after the first ablation, 61% of HIV-positive MSM had recurrent HSILs compared with 38% of HIV negative MSM. One year after the second ablation, 49% of HIVpositive MSM had recurrent HSIL compared with 28% of HIV-negative MSM, and 1 year after the third ablation, 50% of HIV-positive MSM had recurrent HSIL compared with 46% of HIV-negative MSM. It is noteworthy that 82% of HIV-positive MSM and 90% of HIV-negative MSM were free of HSIL at the last visit.
DISCUSSION
Although studies have evaluated the short-term efficacy of IRC ablation of anal HSIL, 11, 14, 21, 25 this is the first study that reports on long-term follow-up in both HIV-positive and HIV-negative MSM. We now present approximately 5 years and 2.5 years longer follow-up for HIV-positive and HIV-negative MSM than in our initial report.
In the present study, we maintain that IRC ablation in both HIV-positive and HIV-negative MSM continues to serve as an effective method to manage anal HSIL. Importantly, no patients in this study progressed to anal SCC, which is the ultimate goal of surveillance and treatment of this high-risk population. Pineda et al 10 reported a progression rate to SCC of 1.2% a mean of 29 months after surgery. Although no prospective, randomized trials exist on the expectant management of HSIL, retrospective studies demonstrate an 8.5% to 13% progression to SCC with expectant management. 9, 26, 27 The effectiveness of IRC ablation in the management of anal HSIL is likely secondary The numbers of patients for each ablation do not necessarily equal the number of patients treated immediately before, because patients without metachronous lesions but who were retreated for a persistent lesion become eligible for follow-up for a potential metachronous recurrence going forward. Therefore, seemingly additional patients at subsequent ablations are those treated for persistent lesions. HSIL ϭ high-grade squamous intraepithelial lesion; IRC ϭ infrared coagulator. a For those who developed a metachronous lesion, this is the number of months from IRC to the time of new HSIL(s), and for those who did not develop a metachronous lesion, it is the follow-up time in months. For those who had a recurrence but did not have a metachronous lesion, this is still the number of months from IRC to the next new HSIL. b HIV-positive patients: Four of 36 patients with metachronous lesions were not retreated with IRC. Five of 8 patients without metachronous lesions remained HSIL free and cannot be followed up any further, leaving 35 patients to be followed up after their second IRC. HIV-negative patients: Six of 27 patients with metachronous lesions were not retreated with IRC. Twenty of 25 patients without metachronous lesions remained HSIL free and cannot be followed up any further. In addition, 1 patient was lost to follow-up after his IRC, leaving 25 patients to be followed up after their second IRC. c HIV-positive patients: One of 16 patients with metachronous lesions were not re-treated with IRC. Thirteen of 19 patients without metachronous lesions remained HSIL free and cannot be followed up any further. In addition, 1 patient was lost to follow-up, leaving 20 patients to be followed up after their third IRC. HIV-negative patients: Five of 12 patients with metachronous lesions were not re-treated with IRC. All 13 patients without metachronous lesions remained HSIL free and cannot be followed up further, leaving 7 patients to be followed up after their third IRC. d HIV-positive patients: Two of 15 patients with metachronous lesions were not re-treated with IRC. Three of 5 patients without metachronous lesions remained HSIL free and cannot be followed up any further, leaving 15 patients to be followed up after their fourth IRC. No HIV-negative patients received a fourth IRC ablation.
to its very high individual lesion cure rate, in both HIVpositive and HIV-negative MSM. The probability of successful ablation of individual high-grade lesions was 67% and 77% after first and second IRC ablation in HIV-positive MSM, respectively, and 80% and 82% after first and second IRC ablation in HIV-negative MSM, respectively. These individual lesion cure rates in HIV-positive patients are similar to previously reported values of between 65% and 72%. 11, 14, 25 Moreover, recurrence rates in HIV-positive women following loop electrosurgical excision of cervical dysplasia are over 55% despite clear margins. 28 Although the cure rates for individual lesions were relatively high regardless of HIV status, HSIL recurrence after first IRC ablation was significantly greater among HIVpositive patients than among HIV-negative patients. In fact, HIV-positive MSM were 1.9 times more likely to have a recurrence after the first IRC treatment. HIV-positive MSM had recurrences twice as quickly as HIV-negative MSM, with a median time to recurrence for HIV-positive MSM vs HIV-negative MSM of 12 Ϯ 1 month vs 24 Ϯ 6 months (P ϭ .008). It is noteworthy, however, that this difference in HSIL recurrence by HIV status HSIL ϭ high-grade squamous intraepithelial lesion; IRC ϭ infrared coagulator; N/A ϭ not applicable. a HIV-positive patients: Two of 27 patients that had persistent lesions did not have their lesion(s) treated with IRC, so they could not be followed up for further persistence. HIV-negative patients: Three of 18 patients that had persistent lesions did not have their lesion(s) treated with IRC, so they could not be followed up for further persistence. b HIV-positive patients: One of 6 patients that had persistent lesions did not have their lesion(s) treated with IRC, so they could not be followed up for further persistence. HIVnegative patients: Neither of the 2 HIV-negative patients who had persistent lesions had their lesions treated with IRC. DISEASES OF THE COLON & RECTUM VOLUME 54: 10 (2011) after the first IRC treatment was not present after the second and third IRC treatments. The equilibration of the recurrence rates between the 2 cohorts may be secondary to the significant reduction in recurrence with each successive IRC treatment among HIV-positive MSM that was not observed among HIV-negative MSM. The reason for reduced recurrence with continued IRC treatment among HIV-positive and not among HIV-negative MSM is unclear and could be related to small sample size. Although no patients developed anal SCC, the recurrence rates and incidence of metachronous lesions remained fairly high, even after the third and fourth IRC treatments. Even though IRC appears to be effective at eradication of individual lesions, the high rate of metachronous lesions indicates the need for continued surveillance. Moreover, surveillance intervals should be guided by HIV status. We report that 50% of HIV-positive MSM will have a recurrence after each ablation within 1 year and that 50% of HIV-negative MSM will have a recurrence within 2 and 4 years after their first and second IRC ablations, respectively. Thus, HIV-positive MSM require shorter surveillance intervals than HIVnegative MSM.
Although we had previously hoped that continued IRC treatment might induce significant disease-free status, especially in HIV-negative individuals, complete cure now appears unlikely. In our original short-term follow-up study on HIV-negative MSM treated for HSIL with successive IRC ablation, success rates after the first, second, and third IRC treatment were 47%, 72%, and 100%. 21 In the present study, on the other hand, success rates after the first, second, and third IRC ablation in HIV-negative MSM were 38%, 52%, and 43%, which is no doubt related to the fact that increased follow-up time leads to ultimate recurrence. It is encouraging, however, that the cure rate of an individual lesion for the first and second IRC treatments with increased follow-up time has remained essentially unchanged. Furthermore, given the long duration of followup, it is possible that lesions categorized for this study as persistent were truly metachronous with recurrence in the same location as the index lesion. The prospect of complete disease eradication by continued local IRC treatment, however, does not appear probable and could be related to frequent HPV reinfection or reactivation over time. As a prior report suggested, testing for oncogenic HPV infection may ultimately be a better predictor of disease-free survival. 29 In addition to the long-term series of Pineda et al, 10 2 other series reported on IRC ablation of HSIL. Cranston et al 25 reported an individual lesion cure rate in 68 HIV-positive patients after a mean of 140 days follow-up of 64%. In a small prospective series of 18 HIVpositive patients, Stier et al 14 reported a lesion cure rate of 66% at 3 months. Our results are clearly consistent with the literature.
Our study has a number of potential limitations. First, this was a retrospective study, and results may not be identical if a prospective study with longer follow-up is performed. Second, although HRA remains the standard for detection of anal dysplasia, it is by no means perfect, and lesions may not have been detected, leading to an underestimation of recurrence rates. Third, the study was performed only on male patients, and these data may not be applicable to other populations. Furthermore, we only performed IRC ablation on biopsy-proven HSIL, and expectant management of HSIL that was not confirmed by biopsy may have lead to increased recurrence rates. Patients with benign cytology and negative standard anoscopy did not undergo HRA and were scored as a nonrecurrence, which could underestimate true recurrence rates. Moreover, it should be noted that patients were excluded from this study if they had extensive disease that was not amenable to in-office IRC ablation. Thus, our results may not be generalized to patients with extensive disease burden. Another limitation of our study relates to the relatively small number of subjects who completed successive ablations. A large number of subjects were lost to followup, reducing our study sample size, and may have limited our ability to discern the true difference in HSIL recurrence following second and third IRC treatments between HIV-negative and HIV-positive subjects. And last, although we are encouraged that 82% of HIV-positive MSM and 90% of HIV-negative MSM were HSIL free at their last visit, the fact remains that over 30% of subjects from the original cohort were not eligible for analysis because they were lost to follow-up.
CONCLUSIONS
IRC ablation is an effective treatment modality for the management of HSIL in both HIV-positive and HIV-negative MSM. HIV-positive patients are significantly more likely to have recurrences, and to have recurrences at much more rapid rates, than HIV-negative MSM. Continued surveillance is necessary because recurrence rates, largely from the development of metachronous lesions, remain high. Future prospective treatment studies are indicated.
